Rational design of a highly immunogenic prefusion-stabilized F glycoprotein antigen for a respiratory syncytial virus vaccine
Science Translational Medicine · 26.04.2023 · 15 (693)
DOI: 10.1126/scitranslmed.ade6422 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Translational Medicine, erschienen am 26.04.2023. Verfasst von Ye Che und 21 weiteren Autor:innen. Beteiligte Einrichtung: Discovery Sciences, Pfizer Inc, Groton, CT 06340, USA. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Vaccines, Respiratory Syncytial Virus Infections, Respiratory Syncytial Virus, Human. Die Arbeit wurde bisher 109-mal zitiert (Crossref) und nennt 59 Literaturangaben.
Abstract (Originalsprache)
Respiratory syncytial virus (RSV) is the leading, global cause of serious respiratory disease in infants and is an important cause of respiratory illness in older adults. No RSV vaccine is currently available. The RSV fusion (F) glycoprotein is a key antigen for vaccine development, and its prefusion conformation is the target of the most potent neutralizing antibodies. Here, we describe a computational and experimental strategy for designing immunogens that enhance the conformational stability and immunogenicity of RSV prefusion F. We obtained an optimized vaccine antigen after screening nearly 400 engineered F constructs. Through in vitro and in vivo characterization studies, we identified F constructs that are more stable in the prefusion conformation and elicit ~10-fold higher serum-neutralizing titers in cotton rats than DS-Cav1. The stabilizing mutations of the lead construct (847) were introduced onto F glycoprotein backbones of strains representing the dominant circulating genotypes of the two major RSV subgroups, A and B. Immunization of cotton rats with a bivalent vaccine formulation of these antigens conferred complete protection against RSV challenge, with no evidence of disease enhancement. The resulting bivalent RSV prefusion F investigational vaccine has recently been shown to be efficacious against RSV disease in two pivotal phase 3 efficacy trials, one for passive protection of infants by immunization of pregnant women and the second for active protection of older adults by direct immunization.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Discovery Sciences, Pfizer Inc, Groton, CT 06340, USA.
- Vaccine Research and Development, Pfizer Inc, Pearl River, NY 10965, USA.
- Children's Foundation Research Institute at Le Bonheur Children's Hospital, Memphis, TN 38103, USA.
ORCID-Profile: Ye Che, Xi Song, Luke D Handke, Kristin Tompkins, Srinivas Kodali, Mark Ammirati, Xiaodi Yu, Joshua A Lees, Lyndsey Martinez, Seungil Han, Kathrin U Jansen, Philip R Dormitzer, Kena A Swanson
Zitieren
APA
Che, Y., Gribenko, A. V., Song, X., Handke, L. D., Efferen, K. S., Tompkins, K., Kodali, S., Nunez, L., Prasad, A. K., Phelan, L. M., Ammirati, M., Yu, X., Lees, J. A., Chen, W., Martinez, L., Roopchand, V., Han, S., Qiu, X., DeVincenzo, J. P., …, & Swanson, K. A. (2023). Rational design of a highly immunogenic prefusion-stabilized F glycoprotein antigen for a respiratory syncytial virus vaccine. Science Translational Medicine, 15(693). https://doi.org/10.1126/scitranslmed.ade6422
Vancouver
Che Y, Gribenko AV, Song X, Handke LD, Efferen KS, Tompkins K, et al. Rational design of a highly immunogenic prefusion-stabilized F glycoprotein antigen for a respiratory syncytial virus vaccine. Science Translational Medicine. 2023;15(693). doi:10.1126/scitranslmed.ade6422
BibTeX
@article{Che2023,
author = {Che, Ye and Gribenko, Alexey V and Song, Xi and Handke, Luke D and Efferen, Kari S and Tompkins, Kristin and Kodali, Srinivas and Nunez, Lorna and Prasad, A Krishna and Phelan, Lynn M and Ammirati, Mark and Yu, Xiaodi and Lees, Joshua A and Chen, Wei and Martinez, Lyndsey and Roopchand, Vidia and Han, Seungil and Qiu, Xiayang and DeVincenzo, John P and Jansen, Kathrin U and Dormitzer, Philip R and Swanson, Kena A},
title = {Rational design of a highly immunogenic prefusion-stabilized F glycoprotein antigen for a respiratory syncytial virus vaccine},
journal = {Science Translational Medicine},
year = {2023},
volume = {15},
number = {693},
doi = {10.1126/scitranslmed.ade6422}
}
EUVIMED